DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line ...
WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2026-- May 22, 2026 — AstraZeneca and Daiichi Sankyo’s DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative …